Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393490

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1393490

APAC Sarcopenia Treatment Market - Industry Trends and Forecast to 2031

PUBLISHED:
PAGES: 241 Pages
DELIVERY TIME: Inquiry
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Description

Table of Contents

List of Tables

The Asia-Pacific sarcopenia treatment market is expected to reach USD 861,882.42 thousand by 2030 from USD 547,450.80 thousand in 2022, growing at a CAGR of 5.9% in the forecast period of 2023 to 2030

Market Segmentation

Asia-Pacific Sarcopenia Treatment Market, By Treatment Type (Medications, Vitamin/Dietary Supplements, and Others), Type (Primary Sarcopenia and Secondary Sarcopenia), Stages (Pre-Sarcopenia, Sarcopenia, and Severe Sarcopenia), Route Of Administration (Oral, Injectable, and Others), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others), Country (Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, New Zealand, Taiwan, And Rest Of Asia-Pacific) - Industry Trends and Forecast to 2030.

Overview of Asia-Pacific Sarcopenia Treatment Market Dynamics

  • Driver
  • Rising prevalence of sarcopenia
  • Restrain
  • Lack of standardized diagnosis
  • Opportunity
  • Strategic initiatives by key market players

Market Players

Some of the key market players operating in the Asia-Pacific sarcopenia treatment market are listed below:

  • Abbott
  • Nestle Health Science (A subsidiary of Nestle S.A.)
  • Novartis AG
  • Sanofi
  • Haleon Group of Companies
  • BASF SE
  • DSM
  • Fermenta Biotech Limited
  • AstaReal Co., Ltd.
  • Metagenics
  • Wellona Pharma
  • The Vitamin Company India
  • Healing Pharma India Pvt. Ltd
  • Others
Show more

TABLE OF CONTENTS

1 INTRODUCTION 30

  • 1.1 OBJECTIVES OF THE STUDY 30
  • 1.2 MARKET DEFINITION 30
  • 1.3 OVERVIEW OF THE ASIA - PACIFIC SARCOPENIA TREATMENT MARKET 30
  • 1.4 CURRENCY AND PRICING 32
  • 1.5 LIMITATIONS 32
  • 1.6 MARKETS COVERED 32

2 MARKET SEGMENTATION 35

  • 2.1 MARKETS COVERED 35
  • 2.2 GEOGRAPHICAL SCOPE 36
  • 2.3 YEARS CONSIDERED FOR THE STUDY 37
  • 2.4 DBMR TRIPOD DATA VALIDATION MODEL 38
  • 2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 41
  • 2.6 MULTIVARIATE MODELLING 42
  • 2.7 TREATMENT TYPE SEGMENT LIFELINE CURVE 42
  • 2.8 MARKET END USER COVERAGE GRID 43
  • 2.9 DBMR MARKET POSITION GRID 44
  • 2.10 VENDOR SHARE ANALYSIS 46
  • 2.11 SECONDARY SOURCES 47
  • 2.12 ASSUMPTIONS 47

3 EXECUTIVE SUMMARY 48

4 PREMIUM INSIGHTS 51

  • 4.1 PESTEL ANALYSIS 52
  • 4.2 PORTER'S FIVE FORCES MODEL 53
  • 4.3 CURRENT STATUS OF EMERGING DRUGS FOR SARCOPENIA TREATMENT 54

5 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: REGULATIONS 55

  • 5.1 REGULATIONS IN U.S. 55
  • 5.2 REGULATIONS IN EUROPE 55
  • 5.3 REGULATIONS IN AUSTRALIA 56
  • 5.4 REGULATIONS IN SOUTH AFRICA 56 

6 MARKET OVERVIEW 57

  • 6.1 DRIVERS 59
    • 6.1.1 RISING PREVALENCE OF SARCOPENIA 59
    • 6.1.2 GROWING AWARENESS OF SARCOPENIA AND ITS DETRIMENTAL EFFECTS ON HEALTH 59
    • 6.1.3 LIFESTYLE FACTORS SUCH AS POOR NUTRITION AND SEDENTARY BEHAVIOUR 60
  • 6.2 RESTRAINTS 61
    • 6.2.1 LACK OF STANDARDIZED DIAGNOSIS 61
    • 6.2.2 HIGH COST OF TREATMENT AND INTERVENTIONS 61
  • 6.3 OPPORTUNITIES 62
    • 6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 62
    • 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 62
  • 6.4 CHALLENGES 63
    • 6.4.1 COMPLICATIONS ASSOCIATED WITH THE SARCOPENIA TREATMENT 63
    • 6.4.2 STRINGENT GOVERNMENT RULES AND REGULATION FOR PRODUCT APPROVAL 64

7 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE 65

  • 7.1 OVERVIEW 66
  • 7.2 VITAMIN/DIETARY SUPPLEMENTS 69
    • 7.2.1 VITAMIN SUPPLEMENTS 70
    • 7.2.2 PROTEIN SUPPLEMENTS 70
    • 7.2.3 FATTY ACID SUPPLEMENTS 70
    • 7.2.4 CREATINE 70
    • 7.2.5 WHEY PROTEINS 70
    • 7.2.6 L-CARNITINE 70
    • 7.2.7 SOY 70
    • 7.2.8 BETA-ALANINE 70
    • 7.2.9 OSTARINE 70
    • 7.2.10 COLLAGEN PEPTIDES 70
    • 7.2.11 LIGANDROL 71
    • 7.2.12 BRANCH-CHAIN AMINO ACIDS 71
    • 7.2.13 HYDROXYMETHYLBUTYRATE (HMB) 71
    • 7.2.14 MEDIUM CHAIN TRIGLYCERIDES 71
    • 7.2.15 OTHERS 71 
  • 7.3 MEDICATIONS 71
    • 7.3.1 OFF LABEL DRUGS 72
    • 7.3.2 EMERGING DRUGS 72
      • 7.3.2.1 ACE INHIBITORS 72
      • 7.3.2.2 APPETITE STIMULANTS 72
      • 7.3.2.3 ORAL ANTIDIABETIC DRUGS 72
      • 7.3.2.4 OTHERS 73
  • 7.4 OTHERS 73

8 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE 74

  • 8.1 OVERVIEW 75
  • 8.2 PRIMARY SARCOPENIA 78
    • 8.2.1 VITAMIN/DIETARY SUPPLEMENTS 78
    • 8.2.2 MEDICATIONS 78
    • 8.2.3 OTHERS 78
  • 8.3 SECONDARY SARCOPENIA 79
    • 8.3.1 VITAMIN/DIETARY SUPPLEMENTS 79
    • 8.3.2 MEDICATIONS 79
    • 8.3.3 OTHERS 79

9 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES 80

  • 9.1 OVERVIEW 81
  • 9.2 PRE-SARCOPENIA 84
  • 9.3 SARCOPENIA 84
  • 9.4 SEVERE SARCOPENIA 85

10 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 86

  • 10.1 OVERVIEW 87
  • 10.2 ORAL 90
  • 10.3 INJECTABLES 90
  • 10.4 OTHERS 91

11 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER 92

  • 11.1 OVERVIEW 93
  • 11.2 MALE 96
  • 11.3 FEMALE 96 

12 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER 97

  • 12.1 OVERVIEW 98
  • 12.2 HOSPITALS 101
    • 12.2.1 PUBLIC 101
    • 12.2.2 PRIVATE 101
  • 12.3 SPECIALTY CLINICS 102
  • 12.4 HOME HEALTHCARE 102
  • 12.5 OTHERS 103

13 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL 104

  • 13.1 OVERVIEW 105
  • 13.2 DIRECT TENDER 108
  • 13.3 RETAIL SALES 108
    • 13.3.1 HOSPITAL PHARMACIES 109
    • 13.3.2 ONLINE PHARMACIES 109
    • 13.3.3 OTHERS 109
  • 13.4 OTHERS 109

14 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY REGION 110

  • 14.1 ASIA-PACIFIC 113
    • 14.1.1 JAPAN 120
    • 14.1.2 CHINA 127
    • 14.1.3 SOUTH KOREA 133
    • 14.1.4 INDIA 139
    • 14.1.5 AUSTRALIA 145
    • 14.1.6 SINGAPORE 151
    • 14.1.7 THAILAND 157
    • 14.1.8 MALAYSIA 163
    • 14.1.9 INDONESIA 169
    • 14.1.10 PHILIPPINES 175
    • 14.1.11 VIETNAM 181
    • 14.1.12 NEW ZEALAND 187
    • 14.1.13 TAIWAN 193
    • 14.1.14 REST OF ASIA-PACIFIC 199

15 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, COMPANY LANDSCAPE 200

  • 15.1 COMPANY SHARE ANALYSIS: ASIA - PACIFIC 200

16 SWOT ANALYSIS 201 

17 COMPANY PROFILE 202

  • 17.1 ABBOTT 202
    • 17.1.1 COMPANY SNAPSHOT 202
    • 17.1.2 REVENUE ANALYSIS 202
    • 17.1.3 COMPANY SHARE ANALYSIS 203
    • 17.1.4 PRODUCT PORTFOLIO 203
    • 17.1.5 RECENT DEVELOPMENT 203
  • 17.2 NESTLE HEALTH SCIENCE (A SUBSIDIARY OF NESTLE S.A.) 204
    • 17.2.1 COMPANY SNAPSHOT 204
    • 17.2.2 REVENUE ANALYSIS 204
    • 17.2.3 COMPANY SHARE ANALYSIS 205
    • 17.2.4 PRODUCT PORTFOLIO 205
    • 17.2.5 RECENT DEVELOPMENT 205
  • 17.3 NOVARTIS AG 206
    • 17.3.1 COMPANY SNAPSHOT 206
    • 17.3.2 REVENUE ANALYSIS 206
    • 17.3.3 COMPANY SHARE ANALYSIS 207
    • 17.3.4 PRODUCT PORTFOLIO 207
    • 17.3.5 PIPELINE PORTFOLIO 207
    • 17.3.6 RECENT DEVELOPMENT 207
  • 17.4 SANOFI 208
    • 17.4.1 COMPANY SNAPSHOT 208
    • 17.4.2 REVENUE ANALYSIS 208
    • 17.4.3 COMPANY SHARE ANALYSIS 209
    • 17.4.4 PRODUCT PORTFOLIO 209
    • 17.4.5 RECENT DEVELOPMENT 209
  • 17.5 HALEON GROUP OF COMPANIES. 210
    • 17.5.1 COMPANY SNAPSHOT 210
    • 17.5.2 REVENUE ANALYSIS 210
    • 17.5.3 COMPANY SHARE ANALYSIS 211
    • 17.5.4 PRODUCT PORTFOLIO 211
    • 17.5.5 RECENT DEVELOPMENT 211
  • 17.6 ASTAREAL CO., LTD. 212
    • 17.6.1 COMPANY SNAPSHOT 212
    • 17.6.2 PRODUCT PORTFOLIO 212
    • 17.6.3 RECENT DEVELOPMENT 212 
  • 17.7 BASF SE 213
    • 17.7.1 COMPANY SNAPSHOT 213
    • 17.7.2 REVENUE ANALYSIS 213
    • 17.7.3 PRODUCT PORTFOLIO 214
    • 17.7.4 RECENT DEVELOPMENT 214
  • 17.8 BIOGEN SA 215
    • 17.8.1 COMPANY SNAPSHOT 215
    • 17.8.2 PRODUCT PORTFOLIO 215
    • 17.8.3 RECENT DEVELOPMENT 215
  • 17.9 BIOTHRIVE SCIENCES 216
    • 17.9.1 COMPANY SNAPSHOT 216
    • 17.9.2 PRODUCT PORTFOLIO 216
    • 17.9.3 RECENT DEVELOPMENT 216
  • 17.10 DSM 217
    • 17.10.1 COMPANY SNAPSHOT 217
    • 17.10.2 REVENUE ANALYSIS 217
    • 17.10.3 PRODUCT PORTFOLIO 218
    • 17.10.4 RECENT DEVELOPMENT 218
  • 17.11 FERMENTA BIOTECH LIMITED 219
    • 17.11.1 COMPANY SNAPSHOT 219
    • 17.11.2 REVENUE ANALYSIS 219
    • 17.11.3 PRODUCT PORTFOLIO 220
    • 17.11.4 RECENT DEVELOPMENT 220
  • 17.12 HEALING PHARMA INDIA PVT. LTD. 221
    • 17.12.1 COMPANY SNAPSHOT 221
    • 17.12.2 PRODUCT PORTFOLIO 221
    • 17.12.3 RECENT DEVELOPMENT 221
  • 17.13 METAGENICS 222
    • 17.13.1 COMPANY SNAPSHOT 222
    • 17.13.2 PRODUCT PORTFOLIO 222
    • 17.13.3 RECENT DEVELOPMENT 222
  • 17.14 THE VITAMIN COMPANY INDIA 223
    • 17.14.1 COMPANY SNAPSHOT 223
    • 17.14.2 PRODUCT PORTFOLIO 223
    • 17.14.3 RECENT DEVELOPMENT 223
  • 17.15 WELLONA PHARMA 224
    • 17.15.1 COMPANY SNAPSHOT 224
    • 17.15.2 PRODUCT PORTFOLIO 224
    • 17.15.3 RECENT DEVELOPMENT 224 
  • 17.16 ARMGO PHARMA, INC. 225
    • 17.16.1 COMPANY SNAPSHOT 225
    • 17.16.2 PIPELINE PORTFOLIO 225
    • 17.16.3 RECENT DEVELOPMENT 225
  • 17.17 BIOPHYTIS 226
    • 17.17.1 COMPANY SNAPSHOT 226
    • 17.17.2 PIPELINE PORTFOLIO 226
    • 17.17.3 RECENT DEVELOPMENT 226
  • 17.18 DYSTROGEN THERAPEUTICS CORP 227
    • 17.18.1 COMPANY SNAPSHOT 227
    • 17.18.2 PIPELINE PORTFOLIO 227
    • 17.18.3 RECENT DEVELOPMENT 227
  • 17.19 IMMUNOFORGE INC. 228
    • 17.19.1 COMPANY SNAPSHOT 228
    • 17.19.2 PIPELINE PORTFOLIO 228
    • 17.19.3 RECENT DEVELOPMENT 228
  • 17.20 MYMD PHARMACEUTICALS 229
    • 17.20.1 COMPANY SNAPSHOT 229
    • 17.20.2 PIPELINE PORTFOLIO 229
    • 17.20.3 RECENT DEVELOPMENT 229
  • 17.21 NMD PHARMA A/S 230
    • 17.21.1 COMPANY SNAPSHOT 230
    • 17.21.2 PIPELINE PORTFOLIO 230
    • 17.21.3 RECENT DEVELOPMENT 230
  • 17.22 ONCOCROSS CO., LTD. 231
    • 17.22.1 COMPANY SNAPSHOT 231
    • 17.22.2 PIPELINE PORTFOLIO 231
    • 17.22.3 RECENT DEVELOPMENT 231
  • 17.23 OPKO HEALTH, INC. 232
    • 17.23.1 COMPANY SNAPSHOT 232
    • 17.23.2 REVENUE ANALYSIS 232
    • 17.23.3 PIPELINE PORTFOLIO 233
    • 17.23.4 RECENT DEVELOPMENT 233
  • 17.24 REGENERON PHARMACEUTICALS INC. 234
    • 17.24.1 COMPANY SNAPSHOT 234
    • 17.24.2 REVENUE ANALYSIS 234
    • 17.24.3 PIPELINE PORTFOLIO 235
    • 17.24.4 RECENT DEVELOPMENT 235 
  • 17.25 REJUVENATE BIOMED NV 236
    • 17.25.1 COMPANY SNAPSHOT 236
    • 17.25.2 PIPELINE PORTFOLIO 236
    • 17.25.3 RECENT DEVELOPMENT 236

18 QUESTIONNAIRE 237

19 RELATED REPORTS 241

Show more

LIST OF TABLES

  • TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT 49
  • TABLE 2 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 63
  • TABLE 3 ASIA - PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 64
  • TABLE 4 ASIA - PACIFIC VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 64
  • TABLE 5 ASIA - PACIFIC MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 66
  • TABLE 6 ASIA - PACIFIC MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 67
  • TABLE 7 ASIA - PACIFIC OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 67
  • TABLE 8 ASIA - PACIFIC OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
  • TABLE 9 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 72
  • TABLE 10 ASIA - PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 73
  • TABLE 11 ASIA - PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 73
  • TABLE 12 ASIA - PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 74
  • TABLE 13 ASIA - PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 74
  • TABLE 14 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 78
  • TABLE 15 ASIA - PACIFIC PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
  • TABLE 16 ASIA - PACIFIC SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 79
  • TABLE 17 ASIA - PACIFIC SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 80
  • TABLE 18 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 84
  • TABLE 19 ASIA - PACIFIC ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
  • TABLE 20 ASIA - PACIFIC INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 85
  • TABLE 21 ASIA - PACIFIC OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 86
  • TABLE 22 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 90
  • TABLE 23 ASIA - PACIFIC MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
  • TABLE 24 ASIA - PACIFIC FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 91
  • TABLE 25 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
  • TABLE 26 ASIA - PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 96
  • TABLE 27 ASIA - PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 96
  • TABLE 28 ASIA - PACIFIC SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
  • TABLE 29 ASIA - PACIFIC HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 97
  • TABLE 30 ASIA - PACIFIC OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 98
  • TABLE 31 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 102
  • TABLE 32 ASIA - PACIFIC DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 103
  • TABLE 33 ASIA - PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 103
  • TABLE 34 ASIA - PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 104
  • TABLE 35 ASIA - PACIFIC OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 104
  • TABLE 36 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 108
  • TABLE 37 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
  • TABLE 38 ASIA-PACIFIC MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
  • TABLE 39 ASIA-PACIFIC OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 109
  • TABLE 40 ASIA-PACIFIC OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 110
  • TABLE 41 ASIA-PACIFIC VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 110
  • TABLE 42 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
  • TABLE 43 ASIA-PACIFIC PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
  • TABLE 44 ASIA-PACIFIC SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 111
  • TABLE 45 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 112
  • TABLE 46 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 112
  • TABLE 47 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 112
  • TABLE 48 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
  • TABLE 49 ASIA-PACIFIC HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 113
  • TABLE 50 ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
  • TABLE 51 ASIA-PACIFIC RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 114
  • TABLE 52 JAPAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
  • TABLE 53 JAPAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
  • TABLE 54 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 115
  • TABLE 55 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 116
  • TABLE 56 JAPAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 116
  • TABLE 57 JAPAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 117
  • TABLE 58 JAPAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
  • TABLE 59 JAPAN PRIMARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
  • TABLE 60 JAPAN SECONDARY SARCOPENIA IN SARCOPENIATREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 118
  • TABLE 61 JAPAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 119
  • TABLE 62 JAPAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 119
  • TABLE 63 JAPAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 119
  • TABLE 64 JAPAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 120
  • TABLE 65 JAPAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 120
  • TABLE 66 JAPAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 120
  • TABLE 67 JAPAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
  • TABLE 68 CHINA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
  • TABLE 69 CHINA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
  • TABLE 70 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 122
  • TABLE 71 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 123
  • TABLE 72 CHINA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 123
  • TABLE 73 CHINA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 124
  • TABLE 74 CHINA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 124
  • TABLE 75 CHINA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 76 CHINA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 125
  • TABLE 77 CHINA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 125
  • TABLE 78 CHINA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 126
  • TABLE 79 CHINA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 126
  • TABLE 80 CHINA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 126
  • TABLE 81 CHINA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 127
  • TABLE 82 CHINA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
  • TABLE 83 CHINA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 127
  • TABLE 84 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
  • TABLE 85 SOUTH KOREA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
  • TABLE 86 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 128
  • TABLE 87 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 129
  • TABLE 88 SOUTH KOREA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 129
  • TABLE 89 SOUTH KOREA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 130
  • TABLE 90 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 130
  • TABLE 91 SOUTH KOREA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
  • TABLE 92 SOUTH KOREA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 131
  • TABLE 93 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 131
  • TABLE 94 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 132
  • TABLE 95 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 132
  • TABLE 96 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 132
  • TABLE 97 SOUTH KOREA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 133
  • TABLE 98 SOUTH KOREA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
  • TABLE 99 SOUTH KOREA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 133
  • TABLE 100 INDIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 101 INDIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 102 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 134
  • TABLE 103 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 135
  • TABLE 104 INDIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 135
  • TABLE 105 INDIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 106 INDIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 136
  • TABLE 107 INDIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
  • TABLE 108 INDIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 137
  • TABLE 109 INDIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 137
  • TABLE 110 INDIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 138
  • TABLE 111 INDIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 138
  • TABLE 112 INDIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 138
  • TABLE 113 INDIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 139
  • TABLE 114 INDIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
  • TABLE 115 INDIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 139
  • TABLE 116 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 117 AUSTRALIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 118 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 140
  • TABLE 119 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 141
  • TABLE 120 AUSTRALIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 141
  • TABLE 121 AUSTRALIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 122 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 142
  • TABLE 123 AUSTRALIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 124 AUSTRALIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 143
  • TABLE 125 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 143
  • TABLE 126 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 144
  • TABLE 127 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 144
  • TABLE 128 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 144
  • TABLE 129 AUSTRALIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 145
  • TABLE 130 AUSTRALIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
  • TABLE 131 AUSTRALIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 145
  • TABLE 132 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 133 SINGAPORE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 134 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 146
  • TABLE 135 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 147
  • TABLE 136 SINGAPORE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 147
  • TABLE 137 SINGAPORE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 148
  • TABLE 138 SINGAPORE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 148
  • TABLE 139 SINGAPORE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
  • TABLE 140 SINGAPORE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 149
  • TABLE 141 SINGAPORE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 149
  • TABLE 142 SINGAPORE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 150
  • TABLE 143 SINGAPORE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 150
  • TABLE 144 SINGAPORE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 150
  • TABLE 145 SINGAPORE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 151
  • TABLE 146 SINGAPORE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
  • TABLE 147 SINGAPORE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 151
  • TABLE 148 THAILAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
  • TABLE 149 THAILAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
  • TABLE 150 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 152
  • TABLE 151 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 153
  • TABLE 152 THAILAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 153
  • TABLE 153 THAILAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 154
  • TABLE 154 THAILAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 154
  • TABLE 155 THAILAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 156 THAILAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 155
  • TABLE 157 THAILAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 155
  • TABLE 158 THAILAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 156
  • TABLE 159 THAILAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 156
  • TABLE 160 THAILAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 156
  • TABLE 161 THAILAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 157
  • TABLE 162 THAILAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
  • TABLE 163 THAILAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 157
  • TABLE 164 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 165 MALAYSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 166 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 158
  • TABLE 167 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 159
  • TABLE 168 MALAYSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 159
  • TABLE 169 MALAYSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 160
  • TABLE 170 MALAYSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 160
  • TABLE 171 MALAYSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 172 MALAYSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 161
  • TABLE 173 MALAYSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 161
  • TABLE 174 MALAYSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 162
  • TABLE 175 MALAYSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 162
  • TABLE 176 MALAYSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 162
  • TABLE 177 MALAYSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 163
  • TABLE 178 MALAYSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 163
  • TABLE 179 MALAYSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 163
  • TABLE 180 INDONESIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 181 INDONESIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 182 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 164
  • TABLE 183 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 165
  • TABLE 184 INDONESIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 165
  • TABLE 185 INDONESIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 186 INDONESIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 166
  • TABLE 187 INDONESIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
  • TABLE 188 INDONESIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 167
  • TABLE 189 INDONESIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 167
  • TABLE 190 INDONESIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 168
  • TABLE 191 INDONESIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 168
  • TABLE 192 INDONESIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 168
  • TABLE 193 INDONESIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 169
  • TABLE 194 INDONESIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
  • TABLE 195 INDONESIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 169
  • TABLE 196 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
  • TABLE 197 PHILIPPINES MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
  • TABLE 198 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 170
  • TABLE 199 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 171
  • TABLE 200 PHILIPPINES OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 171
  • TABLE 201 PHILIPPINES VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 202 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 172
  • TABLE 203 PHILIPPINES PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 204 PHILIPPINES SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 173
  • TABLE 205 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 173
  • TABLE 206 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 174
  • TABLE 207 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 174
  • TABLE 208 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 174
  • TABLE 209 PHILIPPINES HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 175
  • TABLE 210 PHILIPPINES SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
  • TABLE 211 PHILIPPINES RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 175
  • TABLE 212 VIETNAM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 213 VIETNAM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 214 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 176
  • TABLE 215 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 177
  • TABLE 216 VIETNAM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 177
  • TABLE 217 VIETNAM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 218 VIETNAM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 178
  • TABLE 219 VIETNAM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 179
  • TABLE 220 VIETNAM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 179
  • TABLE 221 VIETNAM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 179
  • TABLE 222 VIETNAM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 180
  • TABLE 223 VIETNAM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 180
  • TABLE 224 VIETNAM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 180
  • TABLE 225 VIETNAM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 181
  • TABLE 226 VIETNAM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 181
  • TABLE 227 VIETNAM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 181
  • TABLE 228 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
  • TABLE 229 NEW ZEALAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
  • TABLE 230 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 182
  • TABLE 231 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 183
  • TABLE 232 NEW ZEALAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 183
  • TABLE 233 NEW ZEALAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 184
  • TABLE 234 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 184
  • TABLE 235 NEW ZEALAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 185
  • TABLE 236 NEW ZEALAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 185
  • TABLE 237 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 185
  • TABLE 238 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 186
  • TABLE 239 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 186
  • TABLE 240 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 186
  • TABLE 241 NEW ZEALAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 187
  • TABLE 242 NEW ZEALAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
  • TABLE 243 NEW ZEALAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 187
  • TABLE 244 TAIWAN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 245 TAIWAN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 246 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 188
  • TABLE 247 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME) 189
  • TABLE 248 TAIWAN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP) 189
  • TABLE 249 TAIWAN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 190
  • TABLE 250 TAIWAN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 190
  • TABLE 251 TAIWAN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 191
  • TABLE 252 TAIWAN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 191
  • TABLE 253 TAIWAN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND) 191
  • TABLE 254 TAIWAN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND) 192
  • TABLE 255 TAIWAN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND) 192
  • TABLE 256 TAIWAN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 192
  • TABLE 257 TAIWAN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND) 193
  • TABLE 258 TAIWAN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 193
  • TABLE 259 TAIWAN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 193
  • TABLE 260 REST OF ASIA-PACIFIC SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND) 194

LIST OF FIGURES

  • FIGURE 1 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION 30
  • FIGURE 2 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION 33
  • FIGURE 3 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: DROC ANALYSIS 34
  • FIGURE 4 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: ASIA - PACIFIC VS REGIONAL MARKET ANALYSIS 35
  • FIGURE 5 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS 35
  • FIGURE 6 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS 36
  • FIGURE 7 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID 38
  • FIGURE 8 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID 39
  • FIGURE 9 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS 41
  • FIGURE 10 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: SEGMENTATION 45
  • FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE ASIA - PACIFIC SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030 46
  • FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA - PACIFIC PRECLINICAL MARKET IN 2023 AND 2030 46
  • FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA - PACIFIC SARCOPENIA TREATMENT MARKET 53
  • FIGURE 14 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022 61
  • FIGURE 15 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND) 62
  • FIGURE 16 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030) 62
  • FIGURE 17 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE 63
  • FIGURE 18 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2022 70
  • FIGURE 19 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND) 71
  • FIGURE 20 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030) 71
  • FIGURE 21 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE 72
  • FIGURE 22 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2022 76
  • FIGURE 23 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND) 77
  • FIGURE 24 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030) 77
  • FIGURE 25 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE 78
  • FIGURE 26 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022 82
  • FIGURE 27 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 83
  • FIGURE 28 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030) 83
  • FIGURE 29 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: LIFELINE CURVE 84
  • FIGURE 30 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2022 88
  • FIGURE 31 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND) 89
  • FIGURE 32 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030) 89
  • FIGURE 33 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE 90
  • FIGURE 34 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2022 93
  • FIGURE 35 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND) 94
  • FIGURE 36 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030) 94
  • FIGURE 37 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE 95
  • FIGURE 38 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022 100
  • FIGURE 39 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 101
  • FIGURE 40 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 101
  • FIGURE 41 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND) 102
  • FIGURE 42 ASIA - PACIFIC SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022) 106
  • FIGURE 43 ASIA - PACIFIC SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%) 195
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!